Contact Information: Contact: Dino Luzzi CEO Medivisor, Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 http://www.medivisor.com
Medivisor Inc. to Market Albumax
| Source: Medivisor Inc.
HUNTINGTON STATION, NY--(Marketwire - September 5, 2008) - Medivisor, Inc. (PINKSHEETS : MVSR )
announced today that it has signed an agreement with Cura Pharmaceutical,
Co. Inc to market the product Albumax, a whey protein isolate formula that
makes it easy for kidney disorder patients to reach their daily
requirements of high quality protein in their diet. Under the terms of the
Agreement, Cura will continue to be responsible for manufacturing,
regulatory, medical, clinical development, pricing and distribution for the
product while Medivisor is responsible for sales and marketing.
Kidney disease affects as many as 26 million people, report researchers at
Johns Hopkins University in Baltimore, Tufts-New England Medical Center in
Boston and Cleveland Clinic Foundation. Their findings are published in the
Journal of the American Medical Association. Kidney disease can lead to
kidney failure. It heightens the risk of heart attack, stroke, high blood
pressure and premature death. It causes anemia, bone disease and
malnutrition. According to the National Institutes of Health's US Renal
Data System, by 2020, nearly 785,000 people will be receiving treatment for
kidney failure, costing $53.6 billion.
"Current nutritional supplements either are not designed specifically with
the dialysis patient in mind or do not contain the amount of high quality
whey protein isolate per dose that is in Albumax," stated Fabio Lanzieri,
President of Cura Pharmaceutical Co., Inc.
Protein malnutrition is common in dialysis patients and is a major
contributing factor to morbidity and mortality of these patients. When a
patient relies on dialysis to survive, his nutritional status may suffer
because of his disease, co-existing conditions, and the dialysis therapy
itself. The primary nutrition risk for dialysis patients is protein
malnutrition. Dialysis depletes proteins and amino acids from the blood.
Depleted protein levels in the patient's blood will cause the body to break
down muscle tissue to obtain protein. Dietary allowance for protein for
dialysis patients is 1.2gm/kg/day two-thirds more than in a healthy person.
According to the National Kidney Foundation, serum albumin is a valid and
clinically useful measure of protein-energy nutritional status in
maintenance dialysis patients. A higher serum albumin level is indicative
of better protein nutritional status; the goal is to exceed the lower limit
of the normal range of 4.0g/dL.
A small pilot study of Albumax showed that patient's serum albumin levels
consistently increased while taking Albumax and dropped when they
discontinued use of Albumax. Of the patients that discontinued Albumax and
then restarted, their serum albumin decreased when Albumax was discontinued
and showed increases upon restarting Albumax.
Due to the nature of the dialysis patient's metabolic condition, nutrition
must be closely monitored. Competitive products formulated specifically for
dialysis patients are limited. It has been reported by The National Kidney
Foundation that nutritional interventions that maintain or increase serum
albumin concentrations may be associated with improved long-term survival.
"We are extremely pleased that Cura has chosen Medivisor as their partner
in developing the market for this product in the United States," stated
Dino Luzzi, CEO of Medivisor. "With the announcement of this Agreement we
also launched www.albumax.net which has given the product a web presence.
Over the next few weeks our next initiatives will be to work with the
individual state reimbursement divisions of Medicaid to define Albumax as a
special nutritional composition which is essential for the dietary
management of the disease process."
About Medivisor Inc.:
Medivisor, Inc. is a rapidly growing developer of next-generation focus
driven marketing tools. The company is dedicated to providing technologies
that offer innovative and competitive advantages to the bioscience and
pharmaceutical markets and beyond. From pre-product development through
product launch and commercialization, Medivisor offers worldwide experience
in delivering effective and successful integrated marketing and creative
communications campaigns for the mutual benefit of its clients.
www.medivisor.com
About Cura Pharmaceutical, Co. Inc.:
Cura Pharmaceutical Co., Inc is a New Jersey-Based pharmaceutical marketing
company that focuses on select niche markets through the offering of
specialty products and services. Cura's strategy is to provide products to
the American Healthcare Practitioner and to create partnerships worldwide
that satisfy a distinct unmet medical need and are cost effective. These
products often are not readily accessible and provide enhancements to
existing treatments. Cura's management team has extensive experience in the
industry, with over 100 years of combined pharmaceutical experience.
Safe Harbor
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 (the "Act")
Additionally, words such as "seek," "intend," "believe," "plan,"
"estimate," "expect," "anticipate" and other similar expressions are
forward-looking statements within the meaning of the Act. Some or all of
the events or results anticipated by these forward-looking statements may
not occur. Factors that could cause or contribute to such differences
include the performance ability of the initial units in the field. Further
information on Medivisor risk factors is contained in its filings with the
Securities and Exchange Commission. Medivisor does not undertake any duty
nor does it intend to update the results of these forward-looking
statements.